FDA Approves Next Generation Recombinant Factor VII
Bayer Corporation. NJThe Bayer Corporation announced today that the U.S. Food and Drug Administration approved Kogenate (R) FS Antihemophilic Factor (Recombinant), Formulated with Sucrose [rFVIII FS], a new formulation for the treatment of hemophilia A.